Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients

Simone Negrini, Francesca Spanò, Elena Penza, Daniela Rollando, Francesco Indiveri, Gilberto Filaci, Francesco Puppo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cilostazol is a selective inhibitor of phosphodiesterase-III with antiplatelet, antithrombotic and vasodilating properties. The aim of our study was to evaluate the effect of the drug on vasculopathy and Raynaud’s phenomenon (RP), in a series of patients with systemic sclerosis (SSc), before and after cilostazol treatment. Twenty-one consecutive SSc patients with moderate or severe RP were enrolled in an open-label study. Cilostazol was administered at the dose of 100 mg twice a day, for 12 months. Evaluations included: daily RP attack diary documenting the frequency and duration of RP episodes, Health Assessment Questionnaire-Disability Index, scleroderma visual analogue scales (VAS), flow-mediated dilation and immunological status, including endothelin 1 and interleukin 6 plasma levels. Thirteen patients completed the study. RP duration and daily number episodes recorded over a 3-week period significantly decreased after cilostazol treatment (p = 0.0049 and p = 0.0067, respectively). VAS score indicated a significant amelioration of the patients’ perception of RP (p = 0.0117), and both baseline and post-ischemic brachial artery diameters were significantly increased after cilostazol treatment, as compared with basal values (p = 0.0119 and p = 0.0076, respectively). None of the patients developed digital ulcers during the study. A significant clinical improvement of RP was recorded in SSc patients undergoing cilostazol treatment. Study results indicate a potential role of cilostazol as oral maintenance therapy in SSc patients with RP.

Original languageEnglish
JournalClinical and Experimental Medicine
DOIs
Publication statusAccepted/In press - Jun 19 2015

Fingerprint

Raynaud Disease
Systemic Scleroderma
Visual Analog Scale
Type 3 Cyclic Nucleotide Phosphodiesterases
Therapeutics
Endothelin-1
Brachial Artery
cilostazol
Labels
Interleukin-6
Ulcer
Dilatation
Health
Plasmas
Pharmaceutical Preparations

Keywords

  • Cilostazol
  • Raynaud phenomenon
  • Scleroderma
  • Systemic sclerosis

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients. / Negrini, Simone; Spanò, Francesca; Penza, Elena; Rollando, Daniela; Indiveri, Francesco; Filaci, Gilberto; Puppo, Francesco.

In: Clinical and Experimental Medicine, 19.06.2015.

Research output: Contribution to journalArticle

Negrini, Simone ; Spanò, Francesca ; Penza, Elena ; Rollando, Daniela ; Indiveri, Francesco ; Filaci, Gilberto ; Puppo, Francesco. / Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients. In: Clinical and Experimental Medicine. 2015.
@article{e68a75a1796842e6bfe2023489e5c97d,
title = "Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients",
abstract = "Cilostazol is a selective inhibitor of phosphodiesterase-III with antiplatelet, antithrombotic and vasodilating properties. The aim of our study was to evaluate the effect of the drug on vasculopathy and Raynaud’s phenomenon (RP), in a series of patients with systemic sclerosis (SSc), before and after cilostazol treatment. Twenty-one consecutive SSc patients with moderate or severe RP were enrolled in an open-label study. Cilostazol was administered at the dose of 100 mg twice a day, for 12 months. Evaluations included: daily RP attack diary documenting the frequency and duration of RP episodes, Health Assessment Questionnaire-Disability Index, scleroderma visual analogue scales (VAS), flow-mediated dilation and immunological status, including endothelin 1 and interleukin 6 plasma levels. Thirteen patients completed the study. RP duration and daily number episodes recorded over a 3-week period significantly decreased after cilostazol treatment (p = 0.0049 and p = 0.0067, respectively). VAS score indicated a significant amelioration of the patients’ perception of RP (p = 0.0117), and both baseline and post-ischemic brachial artery diameters were significantly increased after cilostazol treatment, as compared with basal values (p = 0.0119 and p = 0.0076, respectively). None of the patients developed digital ulcers during the study. A significant clinical improvement of RP was recorded in SSc patients undergoing cilostazol treatment. Study results indicate a potential role of cilostazol as oral maintenance therapy in SSc patients with RP.",
keywords = "Cilostazol, Raynaud phenomenon, Scleroderma, Systemic sclerosis",
author = "Simone Negrini and Francesca Span{\`o} and Elena Penza and Daniela Rollando and Francesco Indiveri and Gilberto Filaci and Francesco Puppo",
year = "2015",
month = "6",
day = "19",
doi = "10.1007/s10238-015-0370-5",
language = "English",
journal = "Zeitschrift fü Die Gesamte Experimentelle Medizin",
issn = "1591-8890",
publisher = "Springer-Verlag Italia",

}

TY - JOUR

T1 - Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients

AU - Negrini, Simone

AU - Spanò, Francesca

AU - Penza, Elena

AU - Rollando, Daniela

AU - Indiveri, Francesco

AU - Filaci, Gilberto

AU - Puppo, Francesco

PY - 2015/6/19

Y1 - 2015/6/19

N2 - Cilostazol is a selective inhibitor of phosphodiesterase-III with antiplatelet, antithrombotic and vasodilating properties. The aim of our study was to evaluate the effect of the drug on vasculopathy and Raynaud’s phenomenon (RP), in a series of patients with systemic sclerosis (SSc), before and after cilostazol treatment. Twenty-one consecutive SSc patients with moderate or severe RP were enrolled in an open-label study. Cilostazol was administered at the dose of 100 mg twice a day, for 12 months. Evaluations included: daily RP attack diary documenting the frequency and duration of RP episodes, Health Assessment Questionnaire-Disability Index, scleroderma visual analogue scales (VAS), flow-mediated dilation and immunological status, including endothelin 1 and interleukin 6 plasma levels. Thirteen patients completed the study. RP duration and daily number episodes recorded over a 3-week period significantly decreased after cilostazol treatment (p = 0.0049 and p = 0.0067, respectively). VAS score indicated a significant amelioration of the patients’ perception of RP (p = 0.0117), and both baseline and post-ischemic brachial artery diameters were significantly increased after cilostazol treatment, as compared with basal values (p = 0.0119 and p = 0.0076, respectively). None of the patients developed digital ulcers during the study. A significant clinical improvement of RP was recorded in SSc patients undergoing cilostazol treatment. Study results indicate a potential role of cilostazol as oral maintenance therapy in SSc patients with RP.

AB - Cilostazol is a selective inhibitor of phosphodiesterase-III with antiplatelet, antithrombotic and vasodilating properties. The aim of our study was to evaluate the effect of the drug on vasculopathy and Raynaud’s phenomenon (RP), in a series of patients with systemic sclerosis (SSc), before and after cilostazol treatment. Twenty-one consecutive SSc patients with moderate or severe RP were enrolled in an open-label study. Cilostazol was administered at the dose of 100 mg twice a day, for 12 months. Evaluations included: daily RP attack diary documenting the frequency and duration of RP episodes, Health Assessment Questionnaire-Disability Index, scleroderma visual analogue scales (VAS), flow-mediated dilation and immunological status, including endothelin 1 and interleukin 6 plasma levels. Thirteen patients completed the study. RP duration and daily number episodes recorded over a 3-week period significantly decreased after cilostazol treatment (p = 0.0049 and p = 0.0067, respectively). VAS score indicated a significant amelioration of the patients’ perception of RP (p = 0.0117), and both baseline and post-ischemic brachial artery diameters were significantly increased after cilostazol treatment, as compared with basal values (p = 0.0119 and p = 0.0076, respectively). None of the patients developed digital ulcers during the study. A significant clinical improvement of RP was recorded in SSc patients undergoing cilostazol treatment. Study results indicate a potential role of cilostazol as oral maintenance therapy in SSc patients with RP.

KW - Cilostazol

KW - Raynaud phenomenon

KW - Scleroderma

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84931438604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931438604&partnerID=8YFLogxK

U2 - 10.1007/s10238-015-0370-5

DO - 10.1007/s10238-015-0370-5

M3 - Article

JO - Zeitschrift fü Die Gesamte Experimentelle Medizin

JF - Zeitschrift fü Die Gesamte Experimentelle Medizin

SN - 1591-8890

ER -